StockNow
Calendar
Log in
U.S. Markets

Lilly's (LLY) oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease

StockNow breaking-news AI analysis

The headline reports lower predicted long-term diabetes and cardiovascular risk with Foundayo but lacks study details; earlier ACHIEVE-4 results concern cardiovascular events and are distinct.

1 stocks
LLYEli Lilly & Co.$1,160.10Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Commodities

The US has reportedly told France and Germany to release emergency diesel stocks or face a possible export ban, according to sources

Geopolitics

US President Trump sees a ramping up of bombing Iran after midterms as "possible", reports Time Magazine

Politics

[MARKET UPDATE] Energy benchmarks continue to climb (Brent +1.1%), lifting bond yields (UK 30yr 6%) and weighing on the equity space; European tech sector now flat after opening +0.5%; fresh newsflow light